371R-1

SOX-2 (SP76) Rabbit Monoclonal Antibody

• UNSPSC Code: 12352203
• NACRES: NA.41

Properties

• biological source: rabbit
• Quality Level: 100; 500
• conjugate: unconjugated
• antibody form: culture supernatant
• antibody product type: primary antibodies
• clone: SP76, monoclonal
• description: For In Vitro Diagnostic Use in Select Regions (See Chart)
• form: buffered aqueous solution
• species reactivity: human
• packaging: vial of 0.1 mL concentrate (371R-14); vial of 0.5 mL concentrate (371R-15); bottle of 1.0 mL predilute (371R-17); vial of 1.0 mL concentrate (371R-16); bottle of 7.0 mL predilute (371R-18)
• manufacturer/tradename: Cell Marque^®
• technique(s): immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200
• isotype: IgG
• control: squamous epithelium
• shipped in: wet ice
• storage temp.: 2-8°C
• visualization: nuclear
• Gene Information: human ... SOX2(6657)

Description

General description

It has been reported that anti-SOX-2 antibody recognizes lung squamous cell carcinoma (LSCC). A recent study has demonstrated that extensive anti-SOX-2 staining was seen in over 90% of LSCC and largely paralleled p63 expression. Extensive anti-SOX-2 staining was seen in 21% of lung adenocarcinomas (LACA), including cases that were anti-p63-negative or only anti-p63 focally-positive. However, another recent study showed only 4.5% of LACA is positive for anti-SOX-2 expression. In a study by Sholl et al, 29% of LACA cases exhibited at least focal p63 expression. Combined p63 and SOX-2 expression was seen in 94% of LSCC and 12% of LACA with a statistically significant difference (P<0.0001) versus p63 alone. This study also showed that anti-CK5/6 had a good sensitivity but poor specificity for LSCC. Combined anti-CK5/6 and anti-p63 positivity was seen in 93% of LSCC and 24% of LACA. Anti-CK5/6+/anti-p63+/anti- SOX-2+ was detected in 93% of LSCC and only 9% of LACA. These results indicate that the sensitivity of anti-p63 is equally high but its specificity is similarly variable; it was seen at least focally in close to 30% of LACA. When used together, anti-p63+/anti-SOX-2+ applied to the same tumor cell population is >90% specific for LSCC. Anti-SOX-2 produced moderate-to-intense staining in all 50 cases of embryonal carcinoma components. The only other component that showed reactivity was the primitive neuroectodermal component in 11 of 14 (79%) of immature teratomas. In each of these positive staining foci, the staining varied from moderate-to-strong. Yolk sac tumor, seminoma, mature teratoma, choriocarcinoma, and IGCNU were uniformly negative, as were all the non-neoplastic parenchymal and stromal structures.

Quality

IVD

IVD

IVD

RUO

Linkage

SOX-2 Positive Control Slides, Product No. 371S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany